- Home
- EDIT vs MOBI Comparison
EDIT vs MOBI Comparison
Compare EDIT & MOBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDIT | MOBI |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.6M | 383.0M |
| IPO Year | 2016 | 2026 |
Fundamental Metrics
Financial Performance| Metric | EDIT | MOBI |
|---|---|---|
| Price | $2.64 | $10.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | $6.10 | ★ $17.75 |
| AVG Volume (30 Days) | ★ 2.3M | 140.9K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,937,000.00 | N/A |
| Revenue This Year | N/A | $71.88 |
| Revenue Next Year | N/A | $43.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.64 | N/A |
| 52 Week Low | $1.66 | $8.03 |
| 52 Week High | $3.94 | $15.19 |
Technical Indicators
Market Signals| Indicator | EDIT | MOBI |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 57.18 |
| Support Level | $2.35 | $10.51 |
| Resistance Level | $2.87 | $11.55 |
| Average True Range (ATR) | 0.21 | 0.68 |
| MACD | 0.05 | 0.31 |
| Stochastic Oscillator | 55.10 | 66.83 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
About MOBI Mobia Medical Inc. Common Stock
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.